Topic: autoimmune disease
Brand-new U.K. biotech Izana has kicked off a phase 2a trial of anti-GM-CSF antibody namilumab in ankylosing spondylitis.
Blocking the signaling receptor NLRP3 could treat a range of autoimmune disorders, IFM researchers believe.
The agreement tasks Tsinghua with discovering cancer and autoimmune disease therapeutics that Bristol-Myers can then choose to license.
The €72 million takeover positions Sangamo to move a CAR-carrying regulatory T cell therapy into testing in solid organ transplant patients next year.
HotSpot Therapeutics, a new drug discovery venture exploring protein regulation, has kicked off with $45 million in series A financing.
A new electroporation-based CRISPR-Cas9 method could improve gene editing for CAR-T and other cell therapies.
Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.
Syntimmune has named Vertex’s Mario Saltarelli as chief medical officer, following several leadership changes at the company over the past 18 months.
I-Mab just raised $220 million in a third-round fundraising that once again reveals the strength of China’s emerging biotech sector.
Argenx has data for a subcutaneous formulation of its autoimmune disease drug efgartigimod that could make it a more patient-friendly prospect.